Description

2-[3,5-Bis(Trifluoromethyl)Phenyl]-3,3,3-Trideuterio-n-Methyl-n-[4-(2-Methylphenyl)-6-(4-Methylpiperazin-1-Yl)Pyridin-3-Yl]-2-(Trideuteriomethyl)Propanamide is a deuterated, trifluoromethylated small molecule compound of significant interest in advanced pharmaceutical research and development. Its complex structure, featuring multiple deuterium atoms and trifluoromethyl groups, is specifically engineered to enhance metabolic stability and pharmacokinetic properties in drug candidates. This high-value intermediate is primarily utilized by medicinal chemists and pharmaceutical companies engaged in the discovery of novel therapeutics, particularly for applications in oncology and central nervous system (CNS) disorders.

Application

• Pharmaceutical Intermediate: Serves as a critical building block in the synthesis of deuterated drug candidates for clinical trials.
• Metabolic Stability Studies: Used in research to investigate the effects of deuteration and fluorination on the metabolic profile and half-life of lead compounds.
• Isotope-Labeled Standard: Functions as an internal standard in Liquid Chromatography-Mass Spectrometry (LC-MS) for the quantitative bioanalysis of non-deuterated analogs.
• Medicinal Chemistry Research: Employed in structure-activity relationship (SAR) studies to optimize potency and selectivity of targeted therapies.
• Preclinical Development: Integral to the development of novel therapeutics targeting protein kinases and other key biological pathways.
• Contract Research & Manufacturing (CRO/CMO): Supplied to organizations specializing in custom synthesis for the pharmaceutical industry.

Basic Information

Product Name	2-[3,5-Bis(Trifluoromethyl)Phenyl]-3,3,3-Trideuterio-n-Methyl-n-[4-(2-Methylphenyl)-6-(4-Methylpiperazin-1-Yl)Pyridin-3-Yl]-2-(Trideuteriomethyl)Propanamide
CAS No.	2070015-31-3
Molecular Formula	C31H25D6F6N3O
Molecular Weight	Approx. 597.60 g/mol
Synonyms	2-[3,5-Bis(trifluoromethyl)phenyl]-3,3,3-trideuterio-N-methyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]-2-(trideuteriomethyl)propanamide; Deuterated N-Methyl-N-[4-(o-tolyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-2-(trideuteriomethyl)propanamide; 2070015-31-3; (D6)-Labeled CF3 Pharmaceutical Intermediate; Trideuteriomethyl Propanamide Derivative; Deuterated Kinase Inhibitor Intermediate; [D6]-2-[3,5-Bis(trifluoromethyl)phenyl]-N-methyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]-2-(methyl-d3)propanamide
EINECS	Contact for details

Quality Control

Our products undergo rigorous quality testing to ensure compliance with industry standards. We provide comprehensive analytical data to support your research and regulatory filings. Certificates of Analysis (COA) detailing identity, purity (by HPLC), and isotopic enrichment are available for every batch. Our quality system is designed to meet the stringent requirements of pharmaceutical R&D, with documentation traceable to cGMP principles where applicable.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature (15-25°C) in a dry, well-ventilated area. Keep the container sealed to protect from moisture.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (IR)	Conforms to structure
Identification (NMR)	Conforms to structure
Purity (HPLC)	≥ 95.0%
Isotopic Purity (D-content, MS)	≥ 98 atom % D
Water Content (KF)	≤ 1.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.